← All stocks

Roivant Sciences Ltd.

ROIVPharmaceuticalsLatest filing used: 2026-11-09Filings on SEC EDGAR ↗

Fair value per share

No filings-based value

Too few comparable years of filings.

Last close

$39.52

Nov 13, 2026

How we decide

Ten years of results

Revenue

$8M in FY2026, down 72% on the year before

FY2021: $24MFY2022: $55MFY2023: $32MFY2024: $33MFY2025: $29MFY2026: $8M$30M$60MFY21FY23FY26$8.3M
Show as table
YearRevenue
FY2021$24M
FY2022$55M
FY2023$32M
FY2024$33M
FY2025$29M
FY2026$8M

Shares outstanding

Share count rose 4% over 5 years

FY2022: 670MFY2023: 713MFY2024: 831MFY2025: 725MFY2026: 694M0500M1BFY21FY23FY26693.9M
Show as table
YearShares outstanding
FY2021–
FY2022670M
FY2023713M
FY2024831M
FY2025725M
FY2026694M

No cash earnings in the filings. No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-09. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13. Last close: IEX Historical Data, 2026-11-13.